Meme Kanseri, Kolorektal Kanser, Tiroit Kanseri, Melanom ve Böbrek Hücreli Karsinom gibi çeşitli kalıtsal kanser tiplerinden sorumlu mutasyonların tespiti için günümüzde genetik testler yapılabilmektedir.

logo
login
Oturum aç
Services
Hizmetler
About master page
Genekor Hakkinda
News
News
Contact
Bize Ulasin
TR

SABCS - RxPONDER TRIAL Study

RxPONDER Study Results Demonstrate that the Oncotype DX®
Test Can Now Spare Chemotherapy Use in the Majority of Women
with Node-positive Early-stage Breast Cancer.

SABCS - RxPONDER TRIAL Study

RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women
with Node-positive Early-stage Breast Cancer 

• First results from the independent SWOG Cancer Research Network-led Phase III
study to be presented at the 2020 San Antonio Breast Cancer Symposium
• RxPONDER results from over 5,000 women likely to transform the treatment of
node-positive breast cancer, as the TAILORx study did in node-negative disease 

MADISON, Wis., December 9, 2020 – Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0 to 25. First results from the study, led by the independent SWOG Cancer Research Network, and sponsoredby the National Cancer Institute (NCI), identified the majority of women with 1-3 positive nodes who received no benefit from chemotherapy.

For more information please click here

11.12.2020
Change cookies consent Revoke cookies consent